Homepage

Read about the Oxford Vaccine Centre’s COVID-19 vaccine trial.

Com-COV3: Vaccine study to research third dose booster options for 12-to-15 year-olds –find your closest study site and read the press release

Recruiting Now: Help us investigate the first ever vaccine for Invasive Non-Typhoid Salmonella (iNTS) – The SALVO Trial

If you are aged 18 to 55 years old, in good health and live in the Oxford area, then you may be eligible to take part.

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Structural model of the mosaic-8 RBD-mi3 nanoparticle design.

Fan et al., (in press) https://www.biorxiv.org/content/10.1101/2022.06.28.497989v1
Cohen et al., (2022) Science https://www.science.org/doi/10.1126/science.abq0839

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Professor Sir Andrew Pollard Awarded the James Spence Medal in 2022

Professor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children’s Hospital and Vice Master of St Cross College, Oxford.

Image depicting two vials of different Covid-19 vaccines

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Take part in a clinical trial – see a list of all the trials we are currently recruiting to.

Child being vaccinated

Non-COVID research statement

The Oxford Vaccine Group will be continuing with some of our non-COVID research, particularly our paediatric studies, during the COVID-19 pandemic. This is because as part of these studies we give babies their routine primary immunisations on behalf of their GPs. This reduces the administrative burden on the NHS, allowing them to free up capacity and prioritise their workload to be focused on doing what is necessary to manage the response to the COVID-19 pandemic. The participants also benefit from having the vaccines in the safety of their homes or a convenient location.

Vaccine Knowledge

The Vaccine Knowledge Project aims to be a source of independent information about vaccines and infectious diseases.

See more

Research

Vaccines are a key component of global health policy and are essential in the defence of the health of young children. Our research focuses on the development and evaluation of new and improved vaccines.

Explore

Events and Training

We are committed to providing high quality education and training, together with research updates for medical professionals and all those involved in the area of vaccines and paediatric and adult infectious diseases.

Learn

Get involved

There are a number of ways in which you can get involved in our research, inform our research and find out more about our work. To find out more about any of these options, follow the link below.

Participate

Latest publications

Low-dose IL-2 reduces IL-21+ T cell numbers and induces anti-inflammatory gene expression in type 1 diabetes
Journal article

Zhang J. et al, (2022), Nature Communications
Febrile illness in high-risk children: a prospective, international observational study.
Journal article

van der Velden FJS. et al, (2022), Eur J Pediatr
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article

Mentzer AJ. et al, (2022), Nat Med
Detection of poliovirus in London highlights the value of sewage surveillance.
Journal article

Hill M. and Pollard AJ., (2022), Lancet
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Journal article

Madhavan M. et al, (2022), EBioMedicine

Upcoming events

Introduction to Immunisation Training – face-to-face event

Tuesday, 06 December 2022 to Wednesday, 07 December 2022, 9am - 4pm @ Chinnor Rugby Club Kingsey Road Thame Oxfordshire OX9 3JL

A free 2-day face-to-face training for HCPs working within the BOB (Buckinghamshire, Oxfordshire and Berkshire West) Integrated Care System who are new to the role of administering, promoting and/or advising about vaccines.

18th Annual OVG Immunisation Seminar

Thursday, 16 March 2023, 9am to 4pm @ Kassam Stadium Events & Conference Centre

A one-day seminar targeted at HCPs providing key updates and the latest news on the topic of immunisations.

National Immunisation Schedule Evaluation Consortium

OVG is part of the National Immunisation Schedule Evaluation Consortium; a collaboration between a network of Academic Clinical Research groups and the UK Health Security Agency, with a brief of conducting clinical research relevant to UK immunisation policy

More about NISEC

We’ve made a vaccine, now you can make the difference

We’ve heard about how effective vaccines are, but what do we need for them to have the biggest impact on the coronavirus pandemic?

How to make a vaccine in record time

Vaccines usually take decades to develop – so how is Oxford University's ChAdOx1 nCoV-1 vaccine trial moving so quickly? It comes down to careful planning, extraordinary logistics and a whole lot of help from partners around the world.

Cookies on this website